For very high-risk premenopausal patients (e.g., 4+ positive nodes), clinicians may recommend continuing ovarian function suppression beyond the standard 5 years, sometimes advocating for permanent oophorectomy. This is based on clinical experience and data suggesting a more durable blunting of recurrence risk with permanent ovarian ablation.

Citing powerful long-term data from the SOFT and TEXT trials, some oncologists are leaning away from chemotherapy for premenopausal patients with intermediate Oncotype scores (e.g., <25). They argue that the substantial, proven benefits of ovarian function suppression (OFS) may be equivalent to the chemotherapy benefit seen in trials like TAILORx.

While the SOFT trial established a five-year standard for ovarian function suppression (OFS), new registry data indicates that continuing OFS beyond five years, often towards 10 years or natural menopause, further reduces recurrence risk. This evidence supports considering a longer duration of OFS for many premenopausal women to maximize long-term, robust benefits.

Even patients with "low-risk" advanced ovarian cancer face an 85% chance of recurrence. This high baseline risk justifies aggressive upfront combination therapies, like adding bevacizumab, to maximize the potential for a curative outcome without leaving any options off the table.

Tissue may become insufficient or necrotic after neoadjuvant chemotherapy, leading to failed molecular tests. Securing tissue for comprehensive biomarker analysis at the initial diagnosis is crucial to guide treatment decisions, including PARP inhibitor eligibility.

Achieving remission in ovarian cancer is common, but it's often not sustainable. The strategic use of maintenance therapies, like oral PARP inhibitors, is essential to prolonging the cancer-free period and is a central focus of modern treatment.

For opportunistic salpingectomy to become widespread and reduce ovarian cancer rates, patients must be aware of the option and request it during other abdominal surgeries. This requires public education campaigns to create demand, complementing surgeon training.

Proactive measures like cascade testing and risk-reducing surgeries are lowering new diagnoses. However, improved treatments mean patients are living longer, leading to a larger population of individuals actively managing the disease.

Mirroring success in rectal cancer, a new trial is exploring neoadjuvant immunotherapy for localized, MSI-high endometrial cancer. This strategy could potentially allow patients to avoid surgery and radiation, which is a particularly compelling option for those who wish to preserve their fertility.